Arguments in favour of remdesivir for treating SARS-CoV-2 infections.
作者信息
Ko Wen-Chien, Rolain Jean-Marc, Lee Nan-Yao, Chen Po-Lin, Huang Ching-Tai, Lee Ping-Ing, Hsueh Po-Ren
机构信息
Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Center for Infection Control and Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Aix-Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance 7 Publique-Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 8 Marseille, France; IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.
出版信息
Int J Antimicrob Agents. 2020 Apr;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933. Epub 2020 Mar 6.
Abstract
摘要
相似文献
1
Arguments in favour of remdesivir for treating SARS-CoV-2 infections.支持瑞德西韦治疗新型冠状病毒感染的论据。
Int J Antimicrob Agents. 2020 Apr;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933. Epub 2020 Mar 6.
2
A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir.瑞德西韦：一种有前景的 COVID-19 大流行抗病毒候选药物：小型综述。
Eur J Med Chem. 2020 Sep 1;201:112527. doi: 10.1016/j.ejmech.2020.112527. Epub 2020 Jun 6.
3
Rapid review for the anti-coronavirus effect of remdesivir.瑞德西韦抗冠状病毒作用的快速综述。
Drug Discov Ther. 2020;14(2):73-76. doi: 10.5582/ddt.2020.01015.
4
Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?我们用瑞德西韦（一种老药新包装）找到了治疗新冠病毒肺炎的万灵药了吗？
J R Coll Physicians Edinb. 2020 Jun;50(2):159-161. doi: 10.4997/JRCPE.2020.217.
5
Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process.瑞德西韦的紧急使用授权：透明分配流程的必要性。
JAMA. 2020 Jun 16;323(23):2365-2366. doi: 10.1001/jama.2020.8863.
6
Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19.瑞德西韦用于治疗COVID-19的孤儿药指定的政策影响
JAMA Intern Med. 2020 Oct 1;180(10):1273-1274. doi: 10.1001/jamainternmed.2020.2759.
7
[Not Available].[无可用内容]
Rev Med Suisse. 2020 Jun 10;16(697):1220.
8
[Remdesivir, the antiviral hope against SARS-CoV-2].[瑞德西韦，对抗新型冠状病毒的抗病毒希望]
Rev Esp Quimioter. 2020 Jun;33(3):176-179. doi: 10.37201/req/028.2020. Epub 2020 Apr 1.
9
[Remdesivir for patients with COVID-19].[瑞德西韦用于新型冠状病毒肺炎患者]
Internist (Berl). 2020 Aug;61(8):869-872. doi: 10.1007/s00108-020-00836-7.
10
Treatments for COVID-19: where are we now?2019冠状病毒病的治疗方法：我们目前处于什么阶段？
Br J Community Nurs. 2020 Aug 2;25(8):412-413. doi: 10.12968/bjcn.2020.25.8.412.
引用本文的文献
1
Carboxylesterase Factors Influencing the Therapeutic Activity of Common Antiviral Medications Used for SARS-CoV-2 Infection.影响用于新型冠状病毒感染的常见抗病毒药物治疗活性的羧酸酯酶因素。
Pharmaceutics. 2025 Jun 26;17(7):832. doi: 10.3390/pharmaceutics17070832.
2
Among Patients with COVID-19, should Remdesivir be Used for Treatment? A Systematic Review and Meta-analysis.在新冠肺炎患者中，是否应使用瑞德西韦进行治疗？一项系统评价和荟萃分析。
Acta Med Philipp. 2024 Aug 15;58(14):50-66. doi: 10.47895/amp.vi0.7288. eCollection 2024.
3
The impact of the COVID-19 pandemic on spine care providers and patients.2019年冠状病毒病大流行对脊柱护理提供者和患者的影响。
N Am Spine Soc J. 2020 Apr 29;1:100003. doi: 10.1016/j.xnsj.2020.100003. eCollection 2020 May.
4
Treatment with Remdesivir of Children with SARS-CoV-2 Infection: Experience from a Clinical Hospital in Romania.瑞德西韦治疗儿童新冠病毒感染：来自罗马尼亚一家临床医院的经验
Life (Basel). 2024 Mar 20;14(3):410. doi: 10.3390/life14030410.
5
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.关于COVID-19的药物制剂、免疫疗法和支持性疗法的全面综述。
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
6
Efficacy and Safety of Remdesivir in Hospitalized Pediatric COVID-19: A Retrospective Case-Controlled Study.瑞德西韦治疗住院儿童 COVID-19 的疗效和安全性：一项回顾性病例对照研究。
Ther Clin Risk Manag. 2023 Nov 23;19:949-958. doi: 10.2147/TCRM.S432565. eCollection 2023.
7
Efficacy of Oral Remdesivir Compared to GS-441524 for Treatment of Cats with Naturally Occurring Effusive Feline Infectious Peritonitis: A Blinded, Non-Inferiority Study.口服瑞德西韦对比 GS-441524 治疗自然发生湿性猫传染性腹膜炎的疗效：一项双盲、非劣效性研究。
Viruses. 2023 Aug 1;15(8):1680. doi: 10.3390/v15081680.
8
The Coronaviruses: Past, Present, Future.冠状病毒：过去、现在与未来。
HCA Healthc J Med. 2020 Apr 28;1(2):53-63. doi: 10.36518/2689-0216.1060. eCollection 2020.
9
Combining virtual screening with cis-/trans-cleavage enzymatic assays effectively reveals broad-spectrum inhibitors that target the main proteases of SARS-CoV-2 and MERS-CoV.将虚拟筛选与顺/反式切割酶分析相结合，可有效揭示针对 SARS-CoV-2 和 MERS-CoV 主要蛋白酶的广谱抑制剂。
Antiviral Res. 2023 Aug;216:105653. doi: 10.1016/j.antiviral.2023.105653. Epub 2023 Jun 14.
10
Structure-Based Drug Design of RdRp Inhibitors against SARS-CoV-2.基于结构的 RdRp 抑制剂对 SARS-CoV-2 的药物设计。
Top Curr Chem (Cham). 2023 Jun 15;381(5):22. doi: 10.1007/s41061-023-00432-x.
本文引用的文献
1
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).2019新型冠状病毒（2019-nCoV）的治疗选择。
Nat Rev Drug Discov. 2020 Mar;19(3):149-150. doi: 10.1038/d41573-020-00016-0.
2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）和 2019 年冠状病毒病（COVID-19）：疫情和挑战。
Int J Antimicrob Agents. 2020 Mar;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924. Epub 2020 Feb 17.
3
Chloroquine for the 2019 novel coronavirus SARS-CoV-2.氯喹用于2019新型冠状病毒SARS-CoV-2。
Int J Antimicrob Agents. 2020 Mar;55(3):105923. doi: 10.1016/j.ijantimicag.2020.105923. Epub 2020 Feb 15.
4
Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV.人畜共患冠状病毒带来的新威胁——从非典、中东呼吸综合征到2019新型冠状病毒。
J Microbiol Immunol Infect. 2020 Jun;53(3):365-367. doi: 10.1016/j.jmii.2020.02.001. Epub 2020 Feb 4.
5
Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV.从过去中学习：针对 2019-nCoV 引起的严重急性呼吸道感染的可能紧急预防和治疗选择。
Chembiochem. 2020 Mar 2;21(5):730-738. doi: 10.1002/cbic.202000047. Epub 2020 Feb 25.
6
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
7
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.中国武汉 99 例 2019 年新型冠状病毒肺炎患者的流行病学和临床特征：描述性研究。
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
8
First Case of 2019 Novel Coronavirus in the United States.美国首例 2019 新型冠状病毒病例。
N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.
9
Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.新型冠状病毒感染肺炎在中国武汉的早期传播动力学。
N Engl J Med. 2020 Mar 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. Epub 2020 Jan 29.
10
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
Zotero 插件